ABBV vs SUPN: How AbbVie and Supernus Pharmaceuticals Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SUPN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and SUPN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and SUPN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.

Full ABBV guide

Supernus Pharmaceuticals develops and sells prescription medicines for central nervous system conditions: ADHD, epilepsy, Parkinson's disease and, more recently, postpartum depression. The commercial model is straightforward specialty pharma. Supernus owns or licenses the products, runs its own US sales force calling on neurologists and psychiatrists, and books the revenue net of rebates and channel discounts. Its growth engine is Qelbree, a non-stimulant ADHD treatment that did ~$89 million in net sales in the second quarter of 2026 (up ~15%), alongside GOCOVRI for Parkinson's dyskinesia (~$38 million), ONAPGO, a continuous subcutaneous apomorphine infusion launched in 2025 (~$14 million), and collaboration revenue from ZURZUVAE for postpartum depression (~$35 million), which Supernus acquired when it bought Sage Therapeutics in mid-2025 and which it splits 50/50 with Biogen. Working against that are the legacy products: Trokendi XR and Oxtellar XR each fell ~25% year over year, APOKYN fell ~51%, and other older products fell ~71%.

Full SUPN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
• SUPN drivers: Qelbree as the volume anchor in ADHD; ONAPGO and the device-delivered Parkinson's franchise.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For SUPN, the legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABBV if you believe its drivers more; SUPN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and SUPN guides.

ABBV. The large gap between the trailing GAAP P/E (elevated, reflecting non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 15.7x illustrates why analysts and management prefer adjusted metrics: large upfront licensing and milestone payments depress reported earnings without reducing cash generation. On a free cash flow basis, AbbVie trades at a more modest multiple, and the PEG ratio near 0.91 suggests the consensus earnings growth rate is tracking faster than the headline valuation implies. The 2026 revenue guidance of roughly $67 billion and adjusted EPS of $14.37 to $14.57 would, if achieved, represent meaningful upward re-rating from 2025 reported figures.

SUPN. At ~$43 per share the market values Supernus at roughly 2.4 times enterprise value to 2026 guided revenue and about 12 times forward earnings, which is a discount to profitable specialty pharma peers and reflects both the legacy-product decay and the pending merger. The GAAP loss is largely non-cash: a ~$55 million APOKYN impairment and ~$25 million per quarter of intangible amortization from prior acquisitions sit between adjusted operating earnings of ~$31 million in the quarter and the reported ~$58 million net loss. Because the Indivior exchange ratio is fixed at 1.5401 shares, the practical value of a Supernus share now moves with Indivior's price as much as with Supernus's own results.

Headline figures (approximate, 2026-06-27): ABBV shows revenue (fy 2025, reported) ~$61.2 billion, adjusted diluted eps (fy 2025) $10.00, gaap diluted eps (fy 2025) $2.36, forward p/e (consensus fy 2026 estimate) ~15.7x; SUPN shows revenue (ttm) ~$830M, q2 2026 revenue ~$219M, up ~32% year over year, fy2026 revenue guidance ~$860M to ~$890M, fy2026 adjusted operating earnings guidance ~$150M to ~$180M.

ABBV and SUPN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABBV and SUPN exposure against your real portfolio. It is not an investment adviser.